Request for Covid-19 Impact Assessment of this Report
Fetal bovine serum (FBS) is an ideal growth medium containing several nutrients and optimal combination of growth factors, which make it the most effective growth promoter for almost any cell culture system. In addition, the significantly lower content of antibodies compared to adult and newborn sera minimizes the risk of antibody cross-reaction with cells in culture. FBS finds its application in animal tissue culture and plant tissue culture, while reagents are used in various biotechnology applications such as diagnosis, laboratory research, drug development, and others.
Significant rise in biotechnological R&D pertaining to the introduction of novel biopharmaceuticals has led to an increase in demand for FBS. Moreover, increase in investments and funding for research interventions in both developed and developing countries boost the market growth. However, ethical & scientific concerns associated with the potential misuse of biotechnology research practices and dearth of skilled personnel hamper the market growth. Few fraud cases associated with the production of fetal bovine sera have been reported, which further restrains the growth of the market. Conversely, untapped potential of the emerging economies such as India, China, and others is anticipated to provide lucrative opportunities to the key players involved in the fetal bovine serum market.
The fetal bovine serum media market is segmented based on application, end user, and region. The applications covered in the study include biopharmaceuticals, cell culture, human and animal vaccine production, and others. Depending on end user, the market is classified into biotechnology & pharmaceutical industry, academic institute, and research laboratory. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the global fetal bovine serum market along with the current trends and future estimations to elucidate the imminent investment pockets.
A comprehensive analysis of the factors that drive and restrict the market growth is provided.
A comprehensive quantitative analysis of the industry is provided from 2018 to 2025 to assist stakeholders to capitalize on the prevailing market opportunities.
An extensive analysis of the key segments of the industry helps to understand the global trends in the fetal bovine serum market.
Key players and their strategies are provided to understand the competitive outlook of the industry.
KEY MARKET SEGMENTS
• By Application
o Biopharmaceuticals
o Cell Culture
o Human & Animal Vaccine Production
o Others
• By End User
o Biotechnology & Pharmaceutical Companies
o Academic Institute
o Research Laboratory
• By Region
o North America
• U.S.
• Canada
• Mexico
o Europe
• UK
• France
• Germany
• Italy
• France
• Rest of Europe
o Asia-Pacific
• Japan
• China
• India
• South Korea
• Australia
• Rest of Asia-Pacific
o LAMEA
• Saudi Arabia
• South Africa
• Brazil
• Rest of LAMEA
KEY MARKET PLAYERS
• GE Healthcare
• Merck KGaA (Sigma Aldrich)
• HiMedia Laboratories Pvt., Ltd.
• Bio-Techne
• Biowest
• Biological Industries
• Atlas Biologicals
• Rocky Mountain Biologicals
• PAN-Biotech.
• Thermo Fisher Scientific Inc.
The other players in the value chain include (profiles not included in the report)
• Takara Bio, Inc.
• Cyagen Biosciences
• Tissue Culture Biologicals
• Bovogen Biologicals Pty Ltd.
• TCS Biosciences Ltd.
• Corning Incorporated
• Access Biologicals
• Caisson Laboratories, Inc.
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. Key findings
2.2.1. Top impacting factors
2.2.2. Top investment pockets
2.3. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Parent/Peer Market Overview
3.3. Key Forces Shaping Fetal Bovine Serum Industry/Market
3.3.1. Low bargaining power of suppliers
3.3.2. Moderate bargaining power of buyers
3.3.3. Low threat of substitutes
3.3.4. Low intensity of rivalry
3.3.5. Moderate Threat of Substitution
3.4. Pricing Analysis
3.4.1. Pricing Analysis of Fetal Bovine Serum, By Region, 2018 & 2025
3.5. Market evolution/ Industry roadmap
3.6. Value Chain Analysis
3.7. Impact of government regulations on global fetal bovine serum market
3.8. Industry Pain point analysis
3.9. Case Studies
3.9.1. Case Study 01
3.10. Market dynamics
3.10.1. Drivers
3.10.1.1. Rise in R&D Investment
3.10.1.2. High demand of fetal bovine sera
3.10.1.3. Surge in biopharmaceutical production
3.10.2. Restraints
3.10.2.1. High price
3.10.2.2. Increased use of alternatives
3.10.3. Opportunities
3.10.3.1. Untapped potential of the emerging economies
CHAPTER 4: FETAL BOVINE SERUM MARKET, BY APPLICATION
4.1. Overview
4.2. Biopharmaceuticals
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis by country
4.3. Cell Culture
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis by country
4.4. Human and Animal Vaccine Production
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis by country
4.5. Others
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis by country
CHAPTER 5: FETAL BOVINE SERUM MARKET, BY END USER
5.1. Overview
5.2. Biotechnology & Pharmaceutical Company
5.2.1. Market size and forecast, by region
5.2.2. Market analysis by country
5.3. Academic Institute
5.3.1. Market size and forecast, by region
5.3.2. Market analysis by country
5.4. Research Laboratory
5.4.1. Market size and forecast, by region
5.4.2. Market analysis by country
CHAPTER 6: FETAL BOVINE SERUM MARKET, BY REGION
6.1. Overview
6.2. North America
6.2.1. Key market trends and opportunities
6.2.2. Market size and forecast, by application
6.2.3. Market size and forecast, by end user
6.2.4. Market analysis by country
6.2.4.1. U.S. Market size and forecast, by application
6.2.4.2. Market size and forecast, by end user
6.2.4.3. Canada
6.2.4.4. Canada Market size and forecast, by application
6.2.4.5. Canada Market size and forecast, by end user
6.2.4.6. Mexico Market size and forecast, by application
6.2.4.7. Mexico Market size and forecast, by end user
6.3. Europe
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by application
6.3.3. Europe Market size and forecast, by end user
6.3.4. Europe Market size and forecast, by country
6.3.4.1. UK Market size and forecast, by application
6.3.4.2. UK Market size and forecast, by end user
6.3.4.3. Germany Market size and forecast, by application
6.3.4.4. Germany Market size and forecast, by end user
6.3.4.5. France Market size and forecast, by application
6.3.4.6. France Market size and forecast, by end user
6.3.4.7. Italy Market size and forecast, by application
6.3.4.8. Market size and forecast, by end user
6.3.4.9. Spain Market size and forecast, by application
6.3.4.10. Spain Market size and forecast, by end user
6.3.4.11. Rest of Europe Market size and forecast, by application
6.3.4.12. Rest of Europe Market size and forecast, by end user
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by application
6.4.3. Market size and forecast, by end user
6.4.4. Market size and forecast, by country
6.4.4.1. China Market size and forecast, by application
6.4.4.2. China Market size and forecast, by end user
6.4.4.3. India Market size and forecast, by application
6.4.4.4. India Market size and forecast, by end user
6.4.4.5. Japan Market size and forecast, by application
6.4.4.6. Japan Market size and forecast, by end user
6.4.4.7. South Korea Market size and forecast, by application
6.4.4.8. South Korea Market size and forecast, by end user
6.4.4.9. Australia Market size and forecast, by application
6.4.4.10. Australia Market size and forecast, by end user
6.4.4.11. Rest of Asia-Pacific Market size and forecast, by application
6.4.4.12. Rest of Asia-Pacific Market size and forecast, by end user
6.5. LAMEA
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by application
6.5.3. Market size and forecast, by end user
6.5.4. Market size and forecast, by country
6.5.4.1. Brazil Market size and forecast, by application
6.5.4.2. Brazil Market size and forecast, by end user
6.5.4.3. Saudi Arabia Market size and forecast, by application
6.5.4.4. Saudi Arabia Market size and forecast, by end user
6.5.4.5. Saudi Arabia Market size and forecast, by application
6.5.4.6. Saudi Arabia Market size and forecast, by end user
6.5.4.7. Rest of LAMEA Market size and forecast, by application
6.5.4.8. Rest of LAMEA Market size and forecast, by end user
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. INTRODUCTION
7.1.1. MARKET PLAYER POSITIONING, 2018
7.2. MARKET SHARE ANALYSIS OF TOP PLAYERS, 2018 (%)
7.3. TOP WINNING STRATEGIES
7.4. COMPETITIVE DASHBOARD
7.5. COMPETITIVE HEATMAP
CHAPTER 8: COMPANY PROFILES: FETAL BOVINE SERUM MARKET
8.1. BIO-TECHNE (ATLANTA BIOLOGICS)
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. SERA SCANDIA A/S (BIOWEST
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.3. PAN-BIOTECH
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.4. GE HEALTHCARE (A HEALTHCARE DIVISION OF GE COMPANY)
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.5. HIMEDIA LABORATORIES PVT., LTD
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.6. BIOLOGICAL INDUSTRIES
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.7. ATLAS BIOLOGICALS
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.8. Merck KGAA (SIGMA ALDRICH)
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. ROCKY MOUNTAIN BIOLOGICALS (RMBIO)
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.10. THERMO FISHER SCIENTIFIC INC.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product Portfolio
8.10.5. Business performance
8.11. Other Key Player Profile
8.11.1. Key player snapshot
CHAPTER 9: APPENDIX
TABLE 01. GLOBAL FETAL BOVINE SERUM MARKET, BY APPLICATION, 2018-2025 ($MILLION)
TABLE 02. FETAL BOVINE SERUM MARKET REVENUE FOR BIOPHARMACEUTICALS, BY REGION 2018–2025 ($MILLION)
TABLE 03. FETAL BOVINE SERUM MARKET REVENUE FOR CELL CULTURE, BY REGION 2018–2025($MILLION)
TABLE 04. FETAL BOVINE SERUM MARKET REVENUE FOR HUMAN AND ANIMAL VACCINE PRODUCTION, BY REGION 2018–2025($MILLION)
TABLE 05. FETAL BOVINE SERUM MARKET REVENUE FOR OTHER APPLICATIONS, BY REGION 2018–2025($MILLION)
TABLE 06. FETAL BOVINE SERUM MARKET REVENUE FOR BIOTECHNOLOGY & PHARMACEUTICAL COMPANY, BY REGION 2018–2025($MILLION)
TABLE 07. FETAL BOVINE SERUM MARKET REVENUE FOR ACADEMIC INSTITUTE, BY REGION 2018–2025($MILLION)
TABLE 08. FETAL BOVINE SERUM MARKET REVENUE FOR RESEARCH LABORATORY, BY REGION 2018-2025($MILLION)
TABLE 09. NORTH AMERICA FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2019–2026($MILLION)
TABLE 10. NORTH AMERICA FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2018–2025($MILLION)
TABLE 11. NORTH AMERICA FETAL BOVINE SERUM MARKET REVENUE, BY COUNTRY 2018–2025($MILLION)
TABLE 12. U.S. FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2018–2025($MILLION)
TABLE 13. U.S. FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2018–2025($MILLION)
TABLE 14. CANADA FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2018–2025($MILLION)
TABLE 15. CANADA FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2018–2025($MILLION)
TABLE 16. MEXICO FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2018–2025($MILLION)
TABLE 17. MEXICO FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2018–2025($MILLION)
TABLE 18. EUROPE FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2018–2025($MILLION)
TABLE 19. EUROPE FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2018–2025($MILLION)
TABLE 20. EUROPE FETAL BOVINE SERUM MARKET REVENUE, BY COUNTRY 2018–2025($MILLION)
TABLE 21. UK FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2018–2025($MILLION)
TABLE 22. UK FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2018–2025($MILLION)
TABLE 23. GERMANY FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2018–2025($MILLION)
TABLE 24. GERMANY FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2018–2025($MILLION)
TABLE 25. FRANCE FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2018–2025($MILLION)
TABLE 26. FRANCE FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2018–2025($MILLION)
TABLE 27. ITALY FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2018–2025($MILLION)
TABLE 28. ITALY FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2018–2025($MILLION)
TABLE 29. SPAIN FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2018–2025($MILLION)
TABLE 30. SPAIN FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2018–2025($MILLION)
TABLE 31. REST OF EUROPE FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2018–2025($MILLION)
TABLE 32. REST OF EUROPE FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2018–2025($MILLION)
TABLE 33. ASIA-PACIFIC FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2018–2025($MILLION)
TABLE 34. ASIA-PACIFIC FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2018–2025($MILLION)
TABLE 35. ASIA-PACIFIC FETAL BOVINE SERUM MARKET REVENUE, BY COUNTRY 2018–2025($MILLION)
TABLE 36. CHINA FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2018–2025($MILLION)
TABLE 37. CHINA FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2018–2025($MILLION)
TABLE 38. INDIA FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2018–2025($MILLION)
TABLE 39. INDIA FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2018–2025($MILLION)
TABLE 40. JAPAN FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2018–2025($MILLION)
TABLE 41. JAPAN FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2018–2025($MILLION)
TABLE 42. SOUTH KOREA FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2018–2025($MILLION)
TABLE 43. SOUTH KOREA FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2018–2025($MILLION)
TABLE 44. AUSTRALIA FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2018–2025($MILLION)
TABLE 45. AUSTRALIA FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2018–2025($MILLION)
TABLE 46. REST OF ASIA-PACIFIC FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2018–2025($MILLION)
TABLE 47. REST OF ASIA-PACIFIC FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2018–2025($MILLION)
TABLE 48. LAMEA FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2018–2025($MILLION)
TABLE 49. LAMEA FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2018–2025($MILLION)
TABLE 50. LAMEA FETAL BOVINE SERUM MARKET REVENUE, BY COUNTRY 2018–2025($MILLION)
TABLE 51. BRAZIL FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2018–2025($MILLION)
TABLE 52. BRAZIL FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2018–2025($MILLION)
TABLE 53. SAUDI ARABIA FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2018–2025($MILLION)
TABLE 54. SAUDI ARABIA FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2018–2025($MILLION)
TABLE 55. SOUTH AFRICA FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2018–2025($MILLION)
TABLE 56. AFRICA FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2018–2025($MILLION)
TABLE 57. REST OF LAMEA FETAL BOVINE SERUM MARKET REVENUE, BY APPLICATION 2018–2025($MILLION)
TABLE 58. REST OF LAMEA FETAL BOVINE SERUM MARKET REVENUE, BY END USER 2018–2025($MILLION)
TABLE 59. BIO-TECHNE COMPANY SNAPSHOT
TABLE 60. BIO-TECHNE OPERATING SEGMENTS
TABLE 61. BIO-TECHNE: PRODUCT PORTFOLIO
TABLE 62. SERA SCANDIA: COMPANY SNAPSHOT
TABLE 63. BIOWEST: OPERATING SEGMENTS
TABLE 64. SERA SCANDIA: PRODUCT PORTFOLIO
TABLE 65. PAN: COMPANY SNAPSHOT
TABLE 66. PAN: PRODUCT PORTFOLIO
TABLE 67. GE HEALTHCARE: COMPANY SNAPSHOT
TABLE 68. GE HEALTHCARE: OPERATING SEGMENTS
TABLE 69. GE HEALTHCARE: PRODUCT PORTFOLIO
TABLE 70. HIMEDIA: COMPANY SNAPSHOT
TABLE 71. HIMEDIA: OPERATING SEGMENTS
TABLE 72. GE HEALTHCARE: PRODUCT PORTFOLIO
TABLE 73. BI: COMPANY SNAPSHOT
TABLE 74. BIOLOGICAL INDUSTRIES PRODUCT PORTFOLIO
TABLE 75. ATLAS: COMPANY SNAPSHOT
TABLE 76. ATLAS: PRODUCT PORTFOLIO
TABLE 77. MERCK: COMPANY SNAPSHOT
TABLE 78. MERCK: OPERATING SEGMENTS
TABLE 79. MERCK: PRODUCT PORTFOLIO
TABLE 80. RMBIO: COMPANY SNAPSHOT
TABLE 81. RMBIO: PRODUCT PORTFOLIO
TABLE 82. THERMO FISHER: COMPANY SNAPSHOT
TABLE 83. THERMO FISHER: OPERATING SEGMENTS
TABLE 84. THERMO FISHER: OPERATING SEGMENTS
TABLE 85. LIST OF PATENTS: US
TABLE 86. LIST OF PATENTS: JAPAN
TABLE 87. LIST OF PATENTS: JAPAN
The global digital pathology market was valued at $3,323 million in 2016, and is expected to reach $8,668 million by 2023, registering a CAGR of 14.8% during the forecast period. Digital pathology is defined as an image-based information setting enabled b...
The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines are used to repair, replace, and regenerate tissues & organs that are affected owin...
The medical robotics and computer-assisted surgery is a combination of equipment, accessories, software, and services that aid in performing different functions, such as robotic minimally invasive and non-invasive radiosurgeries, rehabilitation therapies, and hospital & pharmacy automation. Surgical robotics...